On March 29, 2025, the University of Utah received a revised Notice of Award from the National Center for Advancing ...

Four years from now, there could be a dozen or so students from Indiana University of Pennsylvania’s medical school doing ...

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the ...

Ending clinical trials with no warning can put patients at risk.

Research and Development (“R&D”) Expenses: R&D expenses for the three months ended December 31, 2024, were $8.2 million, compared to $13.5 million for the same period in 2023. The decrease was due ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

The Iovance TIL platform has demonstrated promising clinical data across ... may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing ...

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint ...

Tumor inflitrating lymphocyte therapies are a promising type of cellular immunotherapy used to treat a broad range of solid ...

The Clinical Trials Research Pillar in the Division of Biostatistics is at the forefront of innovative clinical trial design ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...